Table V.

Treatment dose and schedule

Dose level	Mitoxantrone	Etoposide	Cytarabine	Midostaurin	Bortezomib	Number Treated	Number Replaced	Number of DLTs
1	-	-	-	50 mg BID PO d 1–14	1.0 mg/m2 IV d 1,4,8,11	6	0	0
2	-	-	-	50 mg BID PO d 1–14	1.3 mg/m2 IV d 1,4,8,11	5	2A	0
3	4 mg/m2 IV d 1–6	40 mg/m2 IV d 1–6	1 g/m2 IV d 1–6	50 mg BID PO d 8–21	1.3 mg/m2 IV d 8,11,15,18	3		1
3*	4 mg/m2 IV d 1–6	40 mg/m2 IV d 1–6	1 g/m2 IV d 1–6	50 mg BID PO d 8–21	1.3 mg/m2 SQ d 8,11,15,18	6		3
3A	4mg/m2 IV d 1–6	40mg/m2 IV d 1–6	1 g/m2 IV d 1–6	50mg BID PO d 8–21	1.0 mg/m2 SQ d 8 and 15	8	1B	2
4	6 mg/m2 IV d 1–6	80 mg/m2 IV d 1–6	1 g/m2 IV d 1–6	50 mg BID PO d 8–21	1.3 mg/m2 SQ d 8 and 15	6	3C	2

^AOne patient developed sepsis on day 10 of cycle 1 and treatment was held. One patient withdrew consent on day 2 of therapy to pursue supportive care.

^BThe patient withdrew consent on day 14 of therapy for non-treatment related reasons.

^COne patient developed sepsis on day 12 of therapy and treatment was held. One patient had doses held beginning on day 18 while undergoing evaluation for a possible ileus. One patient refused to continue treatment on day 19 of therapy because of grade 2 nausea.